AbbVie (ABBV) Change in Receivables (2012 - 2026)

AbbVie (ABBV) has reported Change in Receivables for 15 consecutive years, with $1.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Receivables rose 7952.94% year-over-year to $1.4 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 66.8% increase from a year earlier, with the FY2025 full-year figure at $1.5 billion, up 819.81% from the prior year.
• Change in Receivables was $1.4 billion for Q2 2026 at AbbVie, up from -$87.0 million in the prior quarter.
• Over five years, Change in Receivables peaked at $1.5 billion in Q1 2025 and troughed at -$387.0 million in Q4 2024.
• A 5-year average of $219.7 million and a median of $48.5 million in 2023 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables slumped 17100.0% in 2024 and surged 7952.94% in 2026, its largest moves.
• Over 5 years, Change in Receivables stood at $416.0 million in 2022, then slumped by 181.49% to -$339.0 million in 2023, then dropped by 14.16% to -$387.0 million in 2024, then soared by 58.14% to -$162.0 million in 2025, then jumped by 945.06% to $1.4 billion in 2026.
• The last three Change in Receivables figures came in at $1.4 billion (Q2 2026), -$87.0 million (Q1 2026), and -$162.0 million (Q4 2025), per Business Quant data.